Enliven Therapeutics, Inc. (ELVN) NASDAQ
35.52
-1.99(-5.31%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
35.52
-1.99(-5.31%)
Currency In USD
Address
6200 Lookout Road
Boulder, CO 80301
United States of America (the)
Phone
720 647 8519
Sector
Healthcare
Industry
Biotechnology
Employees
62
First IPO Date
March 12, 2020
| Name | Title | Pay | Year Born |
| Richard A. Fair | CEO, President & Director | 672,656 | 1969 |
| Benjamin Hohl | Chief Financial Officer & Head of Corporate Development | 667,894 | 1989 |
| Joseph Lyssikatos | Co-Founder & Research Fellow | 709,400 | 1965 |
| Helen Louise Collins | Chief Medical Officer | 726,420 | 1963 |
| Samuel S. Kintz | Co-Founder & Head of Pipeline | 956,094 | 1986 |
| Galya D. Blachman | Chief Legal Officer & Head of Business Development | 0 | 1977 |
| Anish Patel | Co-Founder & Chief Operating Officer | 0 | 1981 |
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.